{Reference Type}: Case Reports
{Title}: Long-term efficacy of canakinumab in hyperimmunoglobulin D syndrome.
{Author}: Ozdemir Isik O;Karadag DT;Tekeoglu S;Yazici A;Cefle K;Cefle A;
{Journal}: Int J Rheum Dis
{Volume}: 27
{Issue}: 1
{Year}: 2024 Jan 14
{Factor}: 2.558
{DOI}: 10.1111/1756-185X.14857
{Abstract}: Hyperimmunoglobulin D syndrome (HIDS) is a rare autoinflammatory disorder with autosomal recessive inheritance. It is caused by specific mutations in the mevalonate kinase gene (MVK). No treatment specific to HIDS has been approved to date; however, nonsteroidal anti-inflammatory drugs, steroids, colchicine, tumor necrosis factor-α inhibitors, and anti-interleukin-1 treatments are used, based on case reports and observational studies. Herein, we report a case with recurrent fever and arthritis attacks who did not respond to anakinra and was successfully treated with canakinumab. Long-term remission was achieved without any side effects with 300 mg canakinumab treatment every 4 weeks for 5 years.